103 related articles for article (PubMed ID: 12421984)
1. Anticancer activity of sodium stibogluconate in synergy with IFNs.
Yi T; Pathak MK; Lindner DJ; Ketterer ME; Farver C; Borden EC
J Immunol; 2002 Nov; 169(10):5978-85. PubMed ID: 12421984
[TBL] [Abstract][Full Text] [Related]
2. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines.
Pathak MK; Yi T
J Immunol; 2001 Sep; 167(6):3391-7. PubMed ID: 11544330
[TBL] [Abstract][Full Text] [Related]
3. Luteolin sensitizes the antiproliferative effect of interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells.
Tai Z; Lin Y; He Y; Huang J; Guo J; Yang L; Zhang G; Wang F
Cell Signal; 2014 Mar; 26(3):619-28. PubMed ID: 24333668
[TBL] [Abstract][Full Text] [Related]
4. Interferon-gamma is induced in human peripheral blood immune cells in vitro by sodium stibogluconate/interleukin-2 and mediates its antitumor activity in vivo.
Fan K; Borden E; Yi T
J Interferon Cytokine Res; 2009 Aug; 29(8):451-60. PubMed ID: 19514839
[TBL] [Abstract][Full Text] [Related]
5. Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages.
Fan K; Zhou M; Pathak MK; Lindner DJ; Altuntas CZ; Tuohy VK; Borden EC; Yi T
J Immunol; 2005 Nov; 175(10):7003-8. PubMed ID: 16272361
[TBL] [Abstract][Full Text] [Related]
6. Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects.
Yi T; Elson P; Mitsuhashi M; Jacobs B; Hollovary E; Budd GT; Spiro T; Triozzi P; Borden EC
Oncotarget; 2011 Dec; 2(12):1155-1164. PubMed ID: 22201704
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of SSG and SSG/IFNalpha2 against human prostate cancer xenograft tumors in mice: a role for direct growth inhibition in SSG anti-tumor action.
Li J; Lindner DJ; Farver C; Borden EC; Yi T
Cancer Chemother Pharmacol; 2007 Aug; 60(3):341-9. PubMed ID: 17103170
[TBL] [Abstract][Full Text] [Related]
8. Prolactin activates Stat1 but does not antagonize Stat1 activation and growth inhibition by type I interferons in human breast cancer cells.
Schaber JD; Fang H; Xu J; Grimley PM; Rui H
Cancer Res; 1998 May; 58(9):1914-9. PubMed ID: 9581833
[TBL] [Abstract][Full Text] [Related]
9. Effects of sodium stibogluconate on differentiation and proliferation of human myeloid leukemia cell lines in vitro.
Pathak MK; Hu X; Yi T
Leukemia; 2002 Nov; 16(11):2285-91. PubMed ID: 12399974
[TBL] [Abstract][Full Text] [Related]
10. Interferons activate the p42/44 mitogen-activated protein kinase and JAK-STAT (Janus kinase-signal transducer and activator transcription factor) signalling pathways in hepatocytes: differential regulation by acute ethanol via a protein kinase C-dependent mechanism.
Nguyen VA; Chen J; Hong F; Ishac EJ; Gao B
Biochem J; 2000 Jul; 349(Pt 2):427-34. PubMed ID: 10880341
[TBL] [Abstract][Full Text] [Related]
11. STI571-resistant KT-1 cells are sensitive to interferon-alpha accompanied by the loss of T-cell protein tyrosine phosphatase and prolonged phosphorylation of Stat1.
Shimizu T; Miyakawa Y; Oda A; Kizaki M; Ikeda Y
Exp Hematol; 2003 Jul; 31(7):601-8. PubMed ID: 12842705
[TBL] [Abstract][Full Text] [Related]
12. Resistance to interferons in melanoma cells does not correlate with the expression or activation of signal transducer and activator of transcription 1 (Stat1).
Chawla-Sarkar M; Leaman DW; Jacobs BS; Tuthill RJ; Chatterjee-Kishore M; Stark GR; Borden EC
J Interferon Cytokine Res; 2002 May; 22(5):603-13. PubMed ID: 12060499
[TBL] [Abstract][Full Text] [Related]
13. IFN-beta induces serine phosphorylation of Stat-1 in Ewing's sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7.
Sancéau J; Hiscott J; Delattre O; Wietzerbin J
Oncogene; 2000 Jul; 19(30):3372-83. PubMed ID: 10918594
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of interferon action: in vivo activation of 91 kDa transcription factor.
Korutla L; Kumar R
Anticancer Res; 1996; 16(5A):2789-95. PubMed ID: 8917387
[TBL] [Abstract][Full Text] [Related]
15. IFN-gamma priming up-regulates IFN-stimulated gene factor 3 (ISGF3) components, augmenting responsiveness of IFN-resistant melanoma cells to type I IFNs.
Wong LH; Hatzinisiriou I; Devenish RJ; Ralph SJ
J Immunol; 1998 Jun; 160(11):5475-84. PubMed ID: 9605150
[TBL] [Abstract][Full Text] [Related]
16. Retinoic acid resistance in NB4 APL cells is associated with lack of interferon alpha synthesis Stat1 and p48 induction.
Pelicano L; Brumpt C; Pitha PM; Chelbi-Alix MK
Oncogene; 1999 Jul; 18(27):3944-53. PubMed ID: 10435617
[TBL] [Abstract][Full Text] [Related]
17. IL-1 beta attenuates IFN-alpha beta-induced antiviral activity and STAT1 activation in the liver: involvement of proteasome-dependent pathway.
Tian Z; Shen X; Feng H; Gao B
J Immunol; 2000 Oct; 165(7):3959-65. PubMed ID: 11034404
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine phosphatase inhibitor-3 sensitizes melanoma and colon cancer to biotherapeutics and chemotherapeutics.
Kundu S; Fan K; Cao M; Lindner DJ; Tuthill R; Liu L; Gerson S; Borden E; Yi T
Mol Cancer Ther; 2010 Aug; 9(8):2287-96. PubMed ID: 20682647
[TBL] [Abstract][Full Text] [Related]
19. Expression of interferon alfa signaling components in human alcoholic liver disease.
Nguyen VA; Gao B
Hepatology; 2002 Feb; 35(2):425-32. PubMed ID: 11826419
[TBL] [Abstract][Full Text] [Related]
20. IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis.
Chawla-Sarkar M; Leaman DW; Jacobs BS; Borden EC
J Immunol; 2002 Jul; 169(2):847-55. PubMed ID: 12097388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
